DEB-TACE clinical trials

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

This study is looking at a new way to treat a type of liver cancer that can't be removed with surgery. It combines two immunotherapy drugs, durvalumab and tremelimumab, with a radiation treatment called Y-90 SIRT. The aim is to see if this combination is safe and effective.